SEE Program Strengthens Adherence

Personalized glaucoma coaching program boosts medication adherence and reduces stress in randomized trial

By
Alun Evans
March 4, 2026
3 min

Conexiant

Overview

The Support, Educate, Empower (SEE) program significantly improved medication adherence and reduced glaucoma-related distress compared to standard education. A randomized clinical trial demonstrated that participants in the SEE program had a mean adherence of 78%, with over half achieving at least 80% adherence.

Background

Medication adherence is a critical factor in managing glaucoma, as poor adherence can lead to disease progression and increased healthcare costs. Traditional education methods often fail to engage patients effectively. The SEE program utilizes motivational interviewing and personalized coaching to enhance adherence and reduce distress associated with glaucoma management.

Data Highlights

Group	Mean Adherence (%)	Achieved ≥80% Adherence (%)
SEE Program	78	55
Control Group	58	24

Key Findings

The SEE program improved electronically monitored adherence from 64% at baseline to 78% at 6 months.
55% of SEE participants achieved at least 80% adherence compared to 24% in the control group.
The intervention led to a significant reduction in glaucoma-related distress, particularly in emotional burden and regimen-related distress.
Improvements in adherence exceeded the prespecified minimally important clinical difference.
The program's design allows for scalability and personalization, enhancing its effectiveness compared to traditional methods.

Clinical Implications

Healthcare providers should consider implementing structured, motivational interviewing-based programs like SEE to improve medication adherence in glaucoma patients. Such interventions can also alleviate distress, potentially leading to better overall patient outcomes.

Conclusion

The SEE program demonstrates that personalized coaching and education can significantly enhance medication adherence and reduce distress in glaucoma patients. Future studies should evaluate its long-term impact on clinical outcomes.